Targeted Therapeutics in Non-Small Cell Lung Cancer

Table of Contents

1. Executive Summary

2. Cancer Highlights

3. Methodology

4. Table of Contents

• 4.1 List of boxes
• 4.2 List of tables
• 4.3 Appendices

5. Introduction

• 5.1 Current Treatment Strategies
• 5.2 Disease Definition
• 5.3 Etiology & Pathophysiology
• 5.4 Prognosis
• 5.5 Epidemiology

6. Progress in current treatment strategies

• 6.1 Docetaxel
• 6.2 Vinorelbine
• 6.3 Gemcitabine
• 6.4 Paclitaxel
• 6.5 Pemetrexed
• 6.6 Gefitinib
• 6.7 Erlotinib
• 6.8 Bevacizumab

7. Key Therapeutic Strategies

• 7.1 Apoptosis
• 7.2 Protein Kinase Inhibition - Antiangiogenesis and Antivascular Agents
  • 7.2.1 EGFR and VEGFR as target
• 7.3 Immunotherapy

8. Competitive Landscape in NSCLC Drug Development: The Late Stage Pipeline

• 8.1 Protein Kinase Inhibitors
• 8.2 Apoptotic Inducers
• 8.3 Immunotherapy
• 8.4 Other Therapeutic Strategies

9. Disclaimer

• 9.1 Liability
• 9.2 Completeness

10. Appendix 1. Treatment Guide Lines*

11. Appendix 2 Progress Profiles on Approved Drugs

• 11.1 Docetaxel
• 11.2 Vinorelbine
• 11.3 Gemcitabine
• 11.4 Paclitaxel
• 11.5 Pemetrexed
• 11.6 Gefitinib
• 11.7 Erlotinib

12. Drug Index

13. Company Index

• Box 1: Quick Facts - Docetaxel
• Box 2: Scientific Data on Docetaxel
• Box 3: Quick Facts - Vinorelbine
• Box 4: Scientific Data on Vinorelbine
• Box 5: Quick Facts - Gemcitabine
• Box 6: Scientific Data on gemcitabine
• Box 7: The PIONEER clinical trial
• Box 8: Quick Facts - Pemetrexed
• Box 9: Scientific Data on Pemetrexed
• Box 10: Quick Facts - Gefitinib
• Box 11: Scientific Data on Gefitinib
• Box 12: Expert comment
• Box 13: Quick Facts - Erlotinib

• Table 1: Chemotherapeutic Drugs for Treatment of NSCLC
• Table 2: Clinical Studies of NSCLC Patients With EGFR Mutations
• Table 3: Progress on Bevacizumab
• Table 4: Near Term Approved Drugs for the Treatment of NSCLC
• Table 5: Chemotherapy Drugs off Patent
• Table 6: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.
• Table 7: VTA Agents Under Development
• Table 8: EGFR or VEGFR Inhibitors
• Table 9: FMS-Like Tyrosine Kinases and Their Synonyms
• Table 10: Fms-related Tyrosine Kinase Targets in Development
• Table 11: Protein Kinase Targets in Clinical Trials for Lung Cancer
• Table 12: Cancer Immunotherapy Strategies
• Table 13: Progress on Lapatinib
• Table 14: Progress on ZD6474
• Table 15: Progress on Trastuzumab
• Table 16: Progress on Panitumumab
• Table 17: Progress on Cetuximab
• Table 18: Progress on Neovastat
• Table 19: Progress on Affinitak
• Table 20: Progress on Sorafenib
• Table 21: Progress on Canfosfamide
• Table 22: Progress on Exisulind
• Table 23: Progress on Genasense
• Table 24: Progress on Bexarotene
• Table 25: Progress on IGN101
• Table 26: Progress on CPG 7909
• Table 27: Progress on Vinflunine
• Table 28: Progress on Talabostat
• Table 29: Ongoing Studies
• Table 30: Progress on Xcytrin
• Table 31: Progress on Tirapazamine
• Table 32: Progress on Efaproxiral

• 10. Appendix 1. Treatment Guide Lines*
• 11. Appendix 2. Progress Profiles on Approved Drugs